Spots Global Cancer Trial Database for S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
Official Title: A Phase II Study of S-1 and Irinotecan Combination Chemotherapy in Patients With Advanced Gastric Cancer as a First-Line Therapy
Study ID: NCT00343668
Conditions
Interventions
Study Description
Brief Summary: The primary goal of this phase II trial is to evaluate the response rate of combination chemotherapy with S-1 and Irinotecan in patients with advanced gastric cancer as a first-line therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chonnam National University Hwasun Hospital, Hwasun-gun, Jeolanam-do, Korea, Republic of
Chonbuk National University Hospital, Jeonju, Jeonbuk, Korea, Republic of
Inha University hospital, Inchon, , Korea, Republic of
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, , Korea, Republic of
Yonsei Cancer Center, Seoul, , Korea, Republic of
Seoul Veterans Hospital, Seoul, , Korea, Republic of
Korea Institute of radiological and Medical Sciences, Seoul, , Korea, Republic of
Contact Details
Name: Baek-Yeol Ryoo, M.D., Ph.D.
Affiliation: Korea Institute of Radiological and Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
